Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astex Pharmaceuticals Ltd.

Division of Astex Pharmaceuticals Ltd./metaGen Pharmaceuticals GMBH
www.astex-therapeutics.com

Latest From Astex Pharmaceuticals Ltd.

Asia Deal Watch: BeiGene Leaps Into New Year By Licensing DKK1 Antibody Candidate

BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.

Deals Business Strategies

Deal Watch: Early 2020 Deal-Making Boom Starts With Third Bayer/Evotec R&D Alliance

The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.

Deals Business Strategies

Astex Eyes First Filing For Oral Decitabine On Positive Combo Results

Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.

Cancer Clinical Trials

Convergence appoints John Aston to board

Ion channel drug discovery and development company Convergence has appointed John Aston OBE to its board as a non-executive director. Mr Aston was previously CFO of Cambridge Antibody Technology for 10 years before its sale to AstraZeneca for $1.3bn in 2006. He then served as CFO of Astex Therapeutics.

See All

Company Information

UsernamePublicRestriction

Register